Jonas Halfvarson
Overview
Explore the profile of Jonas Halfvarson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
9544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abushamma S, Yadete T, Nero N, Falloon K, Parker C, Abreu M, et al.
J Crohns Colitis
. 2025 Mar;
PMID: 40066499
Background And Aims: Over 10% of patients with Crohn's disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn's disease...
2.
Marild K, Soderling J, Stephansson O, Axelrad J, Halfvarson J, Broms G, et al.
Am J Gastroenterol
. 2025 Feb;
PMID: 39945675
Introduction: It is uncertain whether the risk of major congenital anomalies (mCAs) is increased in children of women with inflammatory bowel disease (IBD). Methods: We aimed to determine the risk...
3.
Wiland P, Both C, Gaylis N, Cohen R, Halfvarson J, Lemke L, et al.
Adv Ther
. 2025 Feb;
42(3):1360-1392.
PMID: 39907897
Sandoz-adalimumab (SDZ-ADL; Hyrimoz, GP2017) is an adalimumab (ADL) biosimilar approved for the treatment of immune-mediated inflammatory diseases. Here, we review the available literature on SDZ-ADL from controlled and real-world evidence...
4.
Boulouis C, Mouchtaridi E, Muller T, Mak J, Fairlie D, Bergman P, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2414230122.
PMID: 39903121
Mucosal-associated invariant T (MAIT) cells are unconventional T cells that mediate rapid antimicrobial immune responses to antigens derived from microbial riboflavin pathway metabolites presented by the evolutionarily conserved MR1 molecules....
5.
Bergemalm D, Baban B, Ljungqvist O, Halfvarson J
Scand J Gastroenterol
. 2025 Jan;
60(3):243-247.
PMID: 39882844
Background: Patients hospitalized with moderately severe or acute severe ulcerative colitis (UC) may experience metabolic disturbances, including alterations in insulin resistance due to inflammation and the administration of glucocorticoids (GCs)....
6.
Karlqvist S, Sachs M, Eriksson C, Cao Y, Montgomery S, Ludvigsson J, et al.
Am J Gastroenterol
. 2024 Dec;
120(1):260-261.
PMID: 39718002
No abstract available.
7.
Honap S, Jairath V, Sands B, Dulai P, Higgins P, Higgins P, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39681225
Background & Aims: Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design-this...
8.
Granno O, Bergemalm D, Salomon B, Lindqvist C, Hedin C, Carlson M, et al.
Gastroenterology
. 2024 Nov;
PMID: 39608683
Background & Aims: Biomarkers are needed to identify individuals at elevated risk of inflammatory bowel disease. This study aimed to identify protein signatures predictive of inflammatory bowel disease. Methods: Using...
9.
Chen J, Zhang H, Fu T, Zhao J, Nowak J, Kalla R, et al.
EBioMedicine
. 2024 Nov;
110:105443.
PMID: 39536393
Background: This study aims to confirm the associations of air pollution with ulcerative colitis (UC) and Crohn's disease (CD); to explore interactions with genetics and lifestyle; and to characterize potential...
10.
Salomon B, Sudhakar P, Bergemalm D, Andersson E, Granno O, Carlson M, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39495605
Background: Recent genetic and transcriptomic data highlight the need for improved molecular characterisation of inflammatory bowel disease (IBD). Proteomics may advance the delineation of IBD phenotypes since it accounts for...